Cost-utility and budget impact analysis of adding-on apremilast to biologic therapy in the treatment of moderate to severe plaque psoriasis, an Iranian payer perspective

Marzieh Zargaran , Fatemeh Soleymani, Saman Ahmad Nasrollahi, Meysam Seyedifar , Mohammad Mehdi Ashrafian Rahaghi


Background and purpose: Plaque psoriasis is a chronic inflammatory disease with skin manifestations that affect the patients' quality of life negatively. The prevalence of psoriasis is approximately 2-3% worldwide and appears to be still on the increase. Due to the stigma problems, psoriasis has a significant effect on one's life that is often overlooked. The current study aimed to conduct the cost-utility evaluation and budget impact analysis of adding-on apremilast ahead of biologic therapy in the treatment of moderate to severe plaque psoriasis. The psoriatic patients who did not undergo the conventional systemic therapy were eligible to enter the defined sequences.

Experimental approach: An excel-based Markov model with 40 cycles of 3 months, each of which was adopted to compare the outcomes of each exclusively administered sequence in the treatment of moderate to severe plaque psoriasis. Two exclusive therapeutic sequences were considered. In the first sequence, apremilast was followed by biologics and in the second one, biologics were administered initially without apremilast. The results were extrapolated up to 10 years. The designed Markov model was also used in budget impact analysis. The cost-saving potential of the new treatment was accounted for the next 5 years.

Findings/Results: Incremental cost and incremental effect were reported in the base case scenario. Using the sequence consisting apremilast provided an additional 0.10 quality-adjusted life years and decreased total costs by about 11,100 USD per patient. These results were in line with the findings from sensitivity analysis. The cost-saving over 5 years is estimated to be around 30 million dollars for the Iran market following the use of the new treatment.

Conclusion and implications: In the treatment of moderate to severe plaque psoriasis, apremilast supplementation prior to biological treatments is more cost-effective than biological treatment alone.


Budget impact; Cost-utility; Payer perspective; Plaque psoriasis.

Full Text:



Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2010 Results by Cause 1990-2010. 2012.

Available from: ihme-data/gbd-2010-results-cause-1990-2010.

Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205-212.

DOI: 10.1111/jdv.13854.

Cannavò SP, Guarneri F, Giuffrida R, Aragona E, Guarneri C. Evaluation of cutaneous surface parameters in psoriatic patients. Skin Res Technol. 2017;23(1):41-47.

DOI: 10.1111/srt.12299.

Enamandram M, Kimball AB. Psoriasis epidemiology: the interplay of genes and the environment. J Invest Dermatol. 2013;133(2):278-289.

DOI: 10.1038/jid.2012.434.

Danielsen K, Olsen AO, Wilsgaard T, Furberg AS. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol. 2013;168(6):1303-1310.

DOI: 10.1111/bjd.12230.

World Health Organization. Global Report on Psoriasis. 2016. Available from:

Baghestani S, Zare S, Mahboobi AA. Skin disease patterns in Hormozgan, Iran. Int J Dermatol. 2005;44(8):641-645.

DOI: 10.1111/j.1365-4632.2004.02140.x.

Noorbala MT, Kafaie P. Pattern of skin disease in the central Iran, Yazd province. J Pak Assoc Dermatol. 2010;20:137-141.

Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850.

DOI: 10.1016/j.jaad.2008.02.039.

Sivamani RK, Goodarzi H, Garcia MS, Raychaudhuri SP, Wehrli LN, Ono Y, et al. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clin Rev Allergy Immunol. 2013;44(2):121-140.

DOI: 10.1007/s12016-012-8301-7.

Carretero G, Ferrandiz C, Dauden E, Vanaclocha Sebastian F, Gomez-Garcia FJ, Herrera-Ceballos E, et al. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry. J Eur Acad Dermatol Venereol. 2015;29(1):156-163.

DOI: 10.1111/jdv.12492.

Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244-252.

DOI: 10.1111/bjd.13343.

Warren RB, Smith CH, Yiu ZZ, Ashcroft DM, Barker JN, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632-2640.

DOI: 10.1038/jid.2015.208.

Levin AA, Gottlieb AB, Au SC. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. J Drugs Dermatol. 2014;13(7):848-853.

Greater Manchester Medicines Management Group (GMMMG), New Therapies Subgroup. The Sequential Use of Biologic Agents in the Treatment of Chronic or Plaque Psoriasis, for Those Patients, Fulfilling NICE Criteria for a Biologic. 2015. Available from: biologic-agents---sequential-use-in-psoriasis.

Gisondi P, Girolomoni G. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. Drug Des Devel Ther. 2016;10:1763-1770.

DOI: 10.2147/DDDT.S108115.

Bewley A, Barker J, Mughal F, Cawston H, Damera V, Morris J, et al. Cost-effectiveness of apremilast in moderate to severe psoriasis in the United Kingdom. Cogent Medicine. 2018;5:1495593,1-24.

DOI: 10.1080/2331205X.2018.1495593.

Central Bank of Iran. Available from:

Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009;219(3):209-218.

DOI: 10.1159/000233234.

Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118-128.

DOI: 10.1056/NEJMoa0810652.

Pan F, Brazier NC, Shear NH, Jivraj F, Schenkel B, Brown R. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective. Value Health. 2011;14(5):652-656.

DOI: 10.1016/j.jval.2011.01.006.

Royal College of Physicians (UK). National Clinical Guideline Centre (UK). Appendix P: Review to define ‘best supportive care’ for NCGC economic model. 2012. Available from:

Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess. 2006;10(46):1-233,i-iv.

DOI: 10.3310/hta10460.

Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598-606.

DOI: 10.1016/j.jaad.2006.05.027.

Dhana A, Yen H, Yen H, Cho E. All-cause and cause-specific mortality in psoriasis: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(5):1332-1343.

DOI: 10.1016/j.jaad.2018.12.037.

World Health Organization. Life tables by country, Iran (Islamic Republic of). Available from:

Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37-49.

DOI: 10.1016/j.jaad.2015.03.049.

Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387-1399.

DOI: 10.1111/bjd.14164.

Tariff Book for Health Services. 3rd ed. Ministry of Health. Islamic Republic of Iran; 2017. Available from:

Abdoli G. Estimation of social discount rate for Iran. J Econ Res. 2009;9(34):135-156.

Armstrong AW, Koning JW, Rowse S, Tan H, Mamolo C, Kaur M. Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data. Dermatol Ther (Heidelb). 2017;7(1):97-109.

DOI: 10.1007/s13555-016-0153-2.

Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385.

DOI: 10.1038/jid.2012.339.

Torres T, Puig L. Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2018;19(1):23-32.

DOI: 10.1007/s40257-017-0302-0.

Ighani A, Georgakopoulos JR, Walsh S, Shear NH, Yeung J. A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: a Canadian multicenter retrospective study. J Am Acad Dermatol. 2018;78(3):623-626.

DOI: 10.1016/j.jaad.2017.09.060.

Ighani A, Georgakopoulos JR, Shear NH, Walsh S, Yeung J. Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: a multicenter, retrospective study. J Am Acad Dermatol. 2018;79(5):953-956.

DOI: 10.1016/j.jaad.2018.04.043.

Mughal F, Cawston H, Kinahan D, Morris J, Tencer T, Zhang F. Cost-effectiveness of apremilast in moderate to severe psoriasis in Scotland. Value Health. 2015;18(7):A335-A766.

DOI: 10.1016/j.jval.2015.09.553.

Cawston H, Damera V, Ektare V, Shear NH, Tencer T, Liu FF. Cost-effectiveness of apremilast in moderate-to-severe psoriasis in Canada. Value Health. 2016;19(7):A587.

DOI: 10.1016/j.jval.2016.09.1386.


  • There are currently no refbacks.

Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.